MedTrace Logo

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

NCT00674245 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-08-19

No results posted yet for this study

Summary

The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG).

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Pantoprazole

40 mg once daily for 4 weeks

DRUG

Pantoprazole

40 mg once daily improves sleep quality in patients with GERD.

DRUG

placebo

40 mg once daily for 4 weeks

Sponsors & Collaborators

  • Southern Arizona VA Health Care System

    lead FED

Principal Investigators

  • Ronnie Fass, MD · Southern VA Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674245 on ClinicalTrials.gov